Log in

Relevant bibliographies by topics / Rosiglitazone / Journal articles

To see the other types of publications on this topic, follow the link: Rosiglitazone.

Journal articles on the topic 'Rosiglitazone'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Rosiglitazone.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Okami, Nobuya, Purnima Narasimhan, Hideyuki Yoshioka, Hiroyuki Sakata, Gab Seok Kim, Joo Eun Jung, Carolina M. Maier, and Pak H. Chan. "Prevention of JNK Phosphorylation as a Mechanism for Rosiglitazone in Neuroprotection after Transient Cerebral Ischemia: Activation of Dual Specificity Phosphatase." Journal of Cerebral Blood Flow & Metabolism 33, no. 1 (October 3, 2012): 106–14. http://dx.doi.org/10.1038/jcbfm.2012.138.

Full text

Abstract:

Rosiglitazone, a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist, prevents cell death after cerebral ischemia in animal models, but the underlying mechanism has not been clarified. In this study, we examined how rosiglitazone protects neurons against ischemia. Mice treated with rosiglitazone were subjected to 60 minutes of focal ischemia followed by reperfusion. Rosiglitazone reduced infarct volume after ischemia and reperfusion. We show that this neuroprotective effect was reversed with a PPARgM antagonist. Western blot analysis showed a significant increase in expression of phosphorylated stress-activated protein kinases (c-Jun N-terminal kinase (JNK) and p38) in ischemic brain tissue. Rosiglitazone blocked this increase. Furthermore, we observed that rosiglitazone increased expression of the dual-specificity phosphatase 8 (DUSP8) protein and messenger RNA in ischemic brain tissue. Dual-specificity phosphatase 8 is a mitogen-activated protein kinase phosphatase that can dephosphorylate JNK and p38. Another key finding of the present study was that knockdown of DUSP8 in primary cultured cortical neurons that were subjected to oxygen–glucose deprivation diminished rosiglitazone's effect on downregulation of JNK phosphorylation. Thus, rosiglitazone's neuroprotective effect after ischemia is mediated by blocking JNK phosphorylation induced by ischemia via DUSP8 upregulation.

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1180 (December 2007): 34. http://dx.doi.org/10.2165/00128415-200711800-00107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1186 (January 2008): 33. http://dx.doi.org/10.2165/00128415-200811860-00106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1127 (November 2006): 21. http://dx.doi.org/10.2165/00128415-200611270-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1143 (March 2007): 21. http://dx.doi.org/10.2165/00128415-200711430-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 788 (February 2000): 9–10. http://dx.doi.org/10.2165/00128415-200007880-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 788 (February 2000): 10. http://dx.doi.org/10.2165/00128415-200007880-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 850 (May 2001): 11. http://dx.doi.org/10.2165/00128415-200108500-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1400 (May 2012): 37. http://dx.doi.org/10.2165/00128415-201214000-00137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1199 (April 2008): 40–41. http://dx.doi.org/10.2165/00128415-200811990-00123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1206 (June 2008): 27. http://dx.doi.org/10.2165/00128415-200812060-00088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1081 (December 2005): 24. http://dx.doi.org/10.2165/00128415-200510810-00076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1086 (January 2006): 23. http://dx.doi.org/10.2165/00128415-200610860-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1088 (February 2006): 20–21. http://dx.doi.org/10.2165/00128415-200610880-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1091 (March 2006): 20. http://dx.doi.org/10.2165/00128415-200610910-00059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1093 (March 2006): 30–31. http://dx.doi.org/10.2165/00128415-200610930-00104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1110 (July 2006): 15–16. http://dx.doi.org/10.2165/00128415-200611100-00050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1111 (July 2006): 20. http://dx.doi.org/10.2165/00128415-200611110-00059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Barman Balfour, Julia A., and Greg L. Plosker. "Rosiglitazone." Drugs 57, no. 6 (1999): 921–30. http://dx.doi.org/10.2165/00003495-199957060-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Mooradian, Arshag D. "Rosiglitazone." Drugs 57, no. 6 (1999): 931–32. http://dx.doi.org/10.2165/00003495-199957060-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wolffenbuttel, Bruce H. R. "Rosiglitazone." Drugs 57, no. 6 (1999): 931–32. http://dx.doi.org/10.2165/00003495-199957060-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Wagstaff, Antona J., and Karen L. Goa. "Rosiglitazone." Drugs 62, no. 12 (2002): 1805–37. http://dx.doi.org/10.2165/00003495-200262120-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Deeks, Emma D., and Susan J. Keam. "Rosiglitazone." Drugs 67, no. 18 (2007): 2747–79. http://dx.doi.org/10.2165/00003495-200767180-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 885 (January 2002): 10. http://dx.doi.org/10.2165/00128415-200208850-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 890 (February 2002): 11. http://dx.doi.org/10.2165/00128415-200208900-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 916 (August 2002): 11. http://dx.doi.org/10.2165/00128415-200209160-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1279 (November 2009): 30. http://dx.doi.org/10.2165/00128415-200912790-00088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1283 (January 2010): 81. http://dx.doi.org/10.2165/00128415-201012830-00259.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1245 (March 2009): 32–33. http://dx.doi.org/10.2165/00128415-200912450-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1249 (April 2009): 40–41. http://dx.doi.org/10.2165/00128415-200912490-00123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1255 (June 2009): 29. http://dx.doi.org/10.2165/00128415-200912550-00083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Krentz, Andrew J. "Rosiglitazone." Drugs 71, no. 2 (January 2011): 123–30. http://dx.doi.org/10.2165/11585300-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 943 (March 2003): 10. http://dx.doi.org/10.2165/00128415-200309430-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 966 (August 2003): 14–15. http://dx.doi.org/10.2165/00128415-200309660-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 975 (November 2003): 13. http://dx.doi.org/10.2165/00128415-200309750-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1288 (February 2010): 35. http://dx.doi.org/10.2165/00128415-201012880-00108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1297 (April 2010): 45. http://dx.doi.org/10.2165/00128415-201012970-00137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1302 (May 2010): 42. http://dx.doi.org/10.2165/00128415-201013020-00133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1018 (September 2004): 13. http://dx.doi.org/10.2165/00128415-200410180-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1031 (December 2004): 13. http://dx.doi.org/10.2165/00128415-200410310-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1054 (June 2005): 16. http://dx.doi.org/10.2165/00128415-200510540-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1060 (July 2005): 14. http://dx.doi.org/10.2165/00128415-200510600-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1066 (August 2005): 9. http://dx.doi.org/10.2165/00128415-200510660-00022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Rosiglitazone." Reactions Weekly &NA;, no. 1351 (May 2011): 38. http://dx.doi.org/10.2165/00128415-201113510-00135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Cada, Dennis J., Danial E. Baker, and Terri Levien. "Rosiglitazone." Hospital Pharmacy 34, no. 11 (November 1999): 1322–39. http://dx.doi.org/10.1177/001857879903401112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Rosiglitazone." Drugs & Therapy Perspectives 14, no. 6 (September 1999): 1–5. http://dx.doi.org/10.2165/00042310-199914060-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Simon, Dominique. "Rosiglitazone." Primary Care Diabetes 3, no. 2 (May 2009): 123–24. http://dx.doi.org/10.1016/j.pcd.2009.05.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Wolffenbuttel, Bruce HR, Jean-Pierre Sels, and Maya SP Huijberts. "Rosiglitazone." Expert Opinion on Pharmacotherapy 2, no. 3 (March 2001): 467–78. http://dx.doi.org/10.1517/14656566.2.3.467.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Bogatkevich, Galina S., Kristin B. Highland, Tanjina Akter, and Richard M. Silver. "The PPARγAgonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects." Pulmonary Medicine 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/545172.

Full text

Abstract:

We present novel data demonstrating that the expression of PPARγis reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγwith the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites. We conclude that PPARγagonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD. Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor.

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Labelling changes for Avandia [rosiglitazone], Avandamet [rosiglitazone/metformin] and Avaglim [rosiglitazone/glimepiride]." Reactions Weekly &NA;, no. 1291 (March 2010): 4. http://dx.doi.org/10.2165/00128415-201012910-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!